Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
about
Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition.The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitorsPotent Hepatitis C Virus NS5A Inhibitors Containing a Benzidine Core.Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosisApproaches to hepatitis C treatment and cure using NS5A inhibitors
P2860
Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
@en
Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
@nl
type
label
Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
@en
Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
@nl
prefLabel
Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
@en
Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
@nl
P2093
P2860
P1476
Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
@en
P2093
Drew R Bobeck
Franck Amblard
Hongwang Zhang
James H Nettles
Junxing Shi
Longhu Zhou
Philip Tharnish
Satish Chavre
Steven J Coats
Tamara R McBrayer
P2860
P304
P356
10.1016/J.BMCL.2013.02.023
P407
P577
2013-02-13T00:00:00Z